project id: TCGA-BLCA; case submitter id: TCGA-BT-A2LD; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.85; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 2.8; rna integrity number: 7.5; age at index: 78; days to birth: -28673; days to death: 623; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Dead; year of birth: 1933; age at diagnosis: 28673; ajcc clinical t: T3a; ajcc pathologic m: M0; ajcc pathologic n: N1; ajcc pathologic stage: Stage IV; ajcc pathologic t: T3a; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 111.0; icd 10 code: C67.0; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Trigone of bladder; synchronous malignancy: Not Reported; tissue or organ of origin: Trigone of bladder; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: yes; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 49; days to sample procurement: 0; initial weight: 200.0; portion submitter id: TCGA-BT-A2LD-01A-12; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 15.0; percent tumor cells: 85.0; percent tumor nuclei: 90.0;